Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 47 of 47 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/01/21
End: 12/12/23
Due: 12/12/24
Phase: N/A
Priority: Normal
Start: 10/09/20
End: 07/20/22
Due: 07/20/23
Phase: N/A
Priority: Normal
Start: 01/14/19
End: 03/31/20
Due: 03/31/21
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Phase: N/A
Priority: Normal
Start: 07/01/19
End: 09/30/21
Due: 09/30/22
Phase: N/A
Priority: Normal
Start: 10/15/18
End: 12/31/20
Due: 12/31/21
Phase: N/A
Priority: Normal
Start: 02/07/23
End: 12/01/25
Due: 12/01/26
Phase: N/A
Priority: Normal
Start: 01/20/21
End: 01/20/23
Due: 01/20/24
Phase: N/A
Priority: Normal
Start: 02/25/25
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 08/01/17
End: 06/30/21
Due: 06/30/22
Phase: N/A
Priority: Normal
Start: 10/01/23
End: 12/30/24
Due: 12/30/25
Phase: N/A
Priority: Normal
Start: 12/01/16
End: 06/30/21
Due: 06/30/22
Phase: N/A
Priority: Normal
Start: 05/20/21
End: 05/20/23
Due: 05/20/24
Phase: N/A
Priority: Normal
Start: 11/25/22
End: 01/31/26
Due: 01/31/27
Phase: N/A
Priority: Normal
Start: 09/30/16
End: 12/31/21
Due: 12/31/22
Phase: N/A
Priority: Normal
Start: 01/01/24
End: 12/31/28
Due: 12/31/29
Phase: N/A
Priority: Normal
Start: 11/06/19
End: 03/31/23
Due: 03/31/24
Phase: N/A
Priority: Normal
Start: 01/14/25
End: 06/30/27
Due: 06/30/28
Phase: N/A
Priority: Normal
Start: 03/29/24
End: 03/29/27
Due: 03/29/28
Phase: N/A
Priority: Normal
Start: 06/12/22
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 03/01/19
End: 03/01/29
Due: 03/01/30
Phase: N/A
Priority: Normal
Start: 06/01/20
End: 07/01/23
Due: 07/01/24
Phase: N/A
Priority: Normal
Start: 05/15/24
End: 04/20/27
Due: 04/20/28